(3)
Includes options to purchase 4,748 shares of Common Stock that are exercisable within 60 days of April 19, 2022 and 2,374 Restricted Stock Units that will vest within 60 days of April 19, 2022.
(4)
Includes options to purchase 4,748 shares of Common Stock that are exercisable within 60 days of April 19, 2022 and 2,374 Restricted Stock Units that will vest within 60 days of April 19, 2022.
(5)
Includes options to purchase 10,151 shares of Common Stock that are exercisable within 60 days of April 19, 2022.
(6)
Includes options to purchase 12,223 shares of Common Stock that are exercisable within 60 days of April 19, 2022.
(7)
Includes options to purchase 20,278 shares of Common Stock that are exercisable within 60 days of April 19, 2022. Does not include 702 shares of Common Stock beneficially owned by Kalliopi Rombotis, Mr. Rombotis’ mother. Mr. Rombotis disclaims beneficial ownership of the foregoing shares.
(8)
Includes options to purchase 4,748 shares of Common Stock that are exercisable within 60 days of April 19, 2022 and 2,374 Restricted Stock Units that will vest within 60 days of April 19, 2022.
(9)
Includes options to purchase 4,748 shares of Common Stock that are exercisable within 60 days of April 19, 2022 and 2,374 Restricted Stock Units that will vest within 60 days of April 19, 2022.
(10)
Includes options to purchase 5,539 shares of Common Stock that are exercisable within 60 days of April 19, 2022 and 2,770 Restricted Stock Units that will vest within 60 days of April 19, 2022.
(11)
Includes options to purchase 5,539 shares of Common Stock that are exercisable within 60 days of April 19, 2022 and 2,770 Restricted Stock Units that will vest within 60 days of April 19, 2022.
(12)
See footnotes 1 through and including 11.
(13)
Based solely on Schedule 13G filed with the SEC on January 11, 2021. Ikarian Capital, LLC (“Ikarian Capital”) has shared voting power and dispositive power with respect to 400,000 shares; Ikarian Healthcare Master Fund, L.P. (the “Ikarian Fund”) has shared voting and dispositive power with respect to 322,685 shares; Ikarian Healthcare Fund GP, L.P. (“Ikarian GP”) has shared voting and dispositive power with respect to 322,685 shares; Chart Westcott has shared voting power and dispositive power with respect to 400,000 shares; and Neil Shahrestani has shared voting power and dispositive power with respect to 400,000 shares. Ikarian Capital is the investment manager of, and may be deemed to indirectly beneficially own securities owned by, the Ikarian Fund. Ikarian GP is the general partner of, and may be deemed to indirectly beneficially own securities owned by, the Ikarian Fund. Ikarian Capital is also the general partner of, and may be deemed to indirectly beneficially own, securities beneficially owned by Ikarian GP. Ikarian Capital is a sub-advisor for certain separate managed accounts (collectively, the “Managed Accounts”) and may be deemed to indirectly beneficially own securities owned by the Managed Accounts. Ikarian Capital is ultimately owned and controlled by Chart Westcott Living Trust, of which Mr. Westcott serves as the sole trustee (the “Trust”), and Mr. Shahrestani. Accordingly, each of Mr. Westcott, as sole trustee of the Trust, and Mr. Shahrestani may be deemed to indirectly beneficially own securities beneficially owned by, Ikarian Capital. The Ikarian Fund and the Managed Accounts are the record and direct beneficial owners of the securities covered by this statement. The Ikarian Fund disclaims beneficial ownership of the shares held by the Managed Accounts. The address for Ikarian Capital entities is c/o Ikarian Capital, LLC, 100 Crescent Court, Suite 1620, Dallas, Texas 75201.
(14)
Based solely on Schedule 13G filed with the SEC on March 18, 2021. Sphera Global Healthcare Management Ltd. (the “Management Company”) has investment management authority over 281,121 shares held by Sphera Global Healthcare Master Fund and 225,703 shares held directly by Sphera Biotech Master Fund, L.P. The Management Company is managed, controlled, and operated by its general partner, Sphera Global Healthcare GP Ltd. (“Sphera GP”), which is controlled by Sphera Funds Management Ltd. (“Sphera Funds”). Each of the Management Company, Sphera GP, and